Hyperfine Inc. has announced interim results from the CARE PMR study, which were presented at the 2025 Alzheimer's Association International Conference in Toronto, Canada. The study evaluates the efficacy of Hyperfine's Swoop® AI-Powered Portable MRI System in detecting ARIA-E in patients undergoing amyloid-targeting therapies such as Lecanemab. The Swoop® system demonstrated a 100% sensitivity rate in identifying mild to moderate ARIA-E, offering a promising solution to the logistical and financial challenges associated with conventional MRI systems. Researchers from Washington University School of Medicine in St. Louis reported findings from 31 Alzheimer's patients, who were scanned using the Swoop® system within one week of their clinical high-field MRI scans. While the ultra-low-field MRI shows potential as a triage tool, high-field MRI may still be required for comprehensive evaluations in certain cases.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。